Current drug treatment of patients with bulimia nervosa and binge-eating disorder: Selective serotonin reuptake inhibitors versus mood stabilizers

International Journal of Psychiatry in Clinical Practice

Volumn 8, Issue 4, 2004, Pages 235-243

  Bellini, Maurizio ^a   Merli, Marina ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antidepressants; Binge eating disorder; Bulimia; Drug treatment; Stabilizers

Indexed keywords

CITALOPRAM; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGITATION; AKATHISIA; ANTICONVULSANT ACTIVITY; ANXIETY; ATAXIA; BINGE EATING DISORDER; BODY WEIGHT; BULIMIA; CALORIC INTAKE; CLINICAL TRIAL; DATA BASE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; ENERGY EXPENDITURE; FOOD INTAKE; GASTROINTESTINAL DISEASE; GLAUCOMA; HEADACHE; HUMAN; INSOMNIA; LANGUAGE DISABILITY; MEDLINE; MOOD DISORDER; NAUSEA; NEPHROLITHIASIS; NEUROTRANSMISSION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PARESTHESIA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; REVIEW; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; TASTE DISORDER; TREATMENT OUTCOME;

EID: 10044243631     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500410005621     Document Type: Review

References (57)

1. Freeman C (1998) Drug treatment for bulimia nervosa. Neuropsychobiology 37: 72-9.
2. Mauri M, Rudelli R, Somaschini E et al (1996) Neurobiological and psychopharmacological basis in the therapy of bulimia and anorexia. Prog Neuro-Psychopharmacol Biol Psychiatr 20: 207-40.
3. Zhu AJ, Walsh BT (2002) Pharmacologic treatment of eating disorders. Can J Psychiatry 47 (3): 227-34.
4. Hudson JI, Carter WP, Pope HG (1996) Antidepressant treatment of binge-eating disorder: research findings and clinical guidelines. J Clin Psychiatry 57 (8): 73-9.
5. Carter WR Hudson JI, Lalonde JK et al (2003) Pharmacologic treatment of binge eating disorder. Int J Eat Disord 34: S74-88.
6. Bacaltchuk J, Hay P (2003) Antidepressants versus placebo for people with bulimia nervosa (Cochrane Review). In: The Cochrane Library, Issue 2, 2004. Chichester, UK: John Wiley & Sons, Ltd.
7. NICE (National Institute for Clinical Excellence), National Collaborating Centre for Mental Health (2004) Eating disorders: core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders. Chapter 7, 8. London: The British Psychological Society and Gaskell Publishers.
8. Stahl SM (2000) Essential Psychopharmacology - Neuroscientific Basis and Practical Applications, 2nd Edition. Cambridge: Cambridge University Press.
9. Wiseman C, Wendy AH, Halmi CA (1998) Eating disorders. Med Clin North Am 82 (1): 145-59.
10. Advokat C, Kutlesic V (1995) Pharmacotherapy of the eating disorders: a commentary. Neurosci Biobehav Rev 19 (1): 59-66.
11. Mayer LES, Walsh BT (1998) The use of selective serotonin reuptake inhibitors in eating disorders. J Clin Psychiatry 59 (15): 28-34.
12. Borri C, Macchi E, Coli E, et al (2001) Disturbi dell'alimentazione In: Cassano GB, Pancheri P, Pavan L, et al (eds) Trattato italiano di psichiatria, 3rd edition. Milano: Masson.
13. Stahl SM (1998) Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 51: 215-35.
14. Finley PR (1994) Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Ann Pharmacother 28: 1359-68.
15. Lemonick MD (1999) Beyond depression. What do those "mood drugs" really do? Time 153 (19): 74.
16. Mendlewicz J (1999) Predicting response: serotonin reuptake inhibition. Int Clin Psychopharmacol 14 (1): 17-20.
17. Fluoxetine Bulimia Nervosa Collaborative Study Group (1992) Fluoxetine in the treatment of bulimia nervosa: a multicenter, placebo-controlled, double blind trial. Arch Gen Psychiatry 49: 139-47.
18. Goldstein DJ, Wilson MG, Thompson VL et al (1995) Long-term fluoxetine treatment of bulimia nervosa. Br J Psychiatry 166: 660-6.
19. Walsh BT, Wilson GT, Loeb KL et al (1997) Medication and psychotherapy in the treatment of bulimia nervosa. Am J Psychiatry 154 (4): 523-31.
20. Walsh BT, Agras WS, Devlin MJ et al (2000) Fluoxetine for bulimia nervosa following poor response to psychotherapy. Am J Psychiatry 157 (8): 1332-4.
21. Romano SJ, Halmi KA, Sarkar NP et al (2002) A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psychiatry 159 (1): 96-102.
22. Fichter MM, Kruger R, Rief W et al (1996) Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology. J Clin Psychopharmacol 16: 9-18.
23. Hudson JI, McElroy SL, Raymond NC et al (1998) Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. Am J Psychiatry 155 (12): 1756-62.
24. McElroy SL, Casuto LS, Nelson EB et al (2000) Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry 157 (6): 1004-6.
25. Arnold LM, McElroy SL, Hudson JI et al (2002) A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder J Clin Psychiatry 63: 1028-33.
26. McElroy SL, Hudson JI, Malhotra S et al (2003) Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial. J Clin Psychiatry 64 (7): 807-13.
27. Fichter MM, Leibl K, Rief W et al (1991) Fluoxetine versus placebo: a double-blind study with bulimic inpatiens undergoing intensive psychotherapy. Pharmacopsychiatry 24: 1-7.
28. Beumont PJ, Russell JD, Touyz SW et al (1997) Intensive nutritional counselling in bulimia nervosa: a role for supplementation with fluoxetine? Aust N Z J Psychiatry 31: 514-24.
29. Gorman JM, Kent JM (2003) SSRIs and SNRIs: broad spectrum of efficacy beyond mayor depression. J Clin Psychiatry 60 (4): 33-9.
30. El-Giamal N, de Zwaan M, Bailer U et al (2003) Milnacipran in the treatment of bulimia nervosa: a report of 16 cases. Eur Neuropsychopharmacol 13: 73-9.
31. El-Giamal N, de Zwaan M, Bailer U et al (2000) Reboxetine in the treatment of bulimia nervosa: a report of seven cases. Int Clin Psychopharmacol 15 (6): 351-6.
32. Malhotra S, King KH, Welge JA et al (2002) Venlafaxine treatment of binge-eating disorder associated with obesity: a series of 35 patients. J Clin Psychiatry 63: 802-6.
33. Marcus MD, Wing RR, Ewing L et al (1990) A double-blind, placebo controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge eaters. Am J Psychiatry 147: 876-81.
34. De Zwaan M, Nutzinger DO, Schoenbeck G (1992) Binge eating in overweight women. Compr Psychiatry 33: 256-61.
35. Fichter MM, Leibl C, Kruger R, Rief W (1997) Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa. Pharmacopsychiatry 30 (3): 85-92.
36. Kiss A (2000) Treatment of chronic bulimic symptoms: new answers, more questions. Lancet 355 (9206): 769-70.
37. Privitera MD (1997) Topiramate: a new antiepileptic drug. Ann Pharmacother 31: 1164-73.
38. Marcotte D (1998) Use of topiramate, a new antiepileptic, as a mood stabilizer. J Affect Disord 50: 245-51.
39. Nieto-Barrera M (2002) Characteristics and indications of topiramate. Rev Neurol 35 (Suppl.1): 88-95.
40. Appolinario JC, Fontenelle LF, Papelbaum M et al (2002) Topiramate use in obese patients with binge eating disorder: an open study. Can J Psychiatry 47 (3): 271-3.
41. McElroy SL, Arnold LM, Shapira NA et al (2003) Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 160 (2): 255-61.
42. Shapira NA, Goldsmith TD, McElroy SL (2000) Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 61 (5): 368-72.
43. Knable MB (2001) Topiramate for bulimia nervosa in epilepsy Am J Psychiatry 158 (2): 322-3.
44. Felstrom A, Blackshaw S (2002) Topiramate for bulimia nervosa with bipolar II disorder. Am J Psychiatry 159 (7): 1246-7.
45. Barbee JG (2003) Topiramate in the treatment of severe bulimia nervosa with comorbid mood disorders: a case series. Int J Eat Disord 33: 468-72.
46. Hoopes SP, Reimherr FW, Hedges DW et al (2003) Treatment of bulimia nervosa with topiramate in a randomized, double blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry 64 (11): 1335-41.
47. Hedges DW, Reimherr FW, Hoopes SP et al (2003) Treatment of bulimia nervosa with topiramate in a randomized, double blind, placebo controlled trial, part 2: improvement in psychiatric measures. J Clin Psychiatry 64 (12): 1449-54.
48. Bacaltchuck J, Hay P, Trefiglio R (2003) Antidepressants versus psychological treatments and their combination for bulimia nervosa (Cochrane Review). In: The Cochrane Library, Issue 2, 2004. Chichester, UK: John Wiley & Sons, Ltd.
49. Casper RC (2002) How useful are pharmacological treatments in eating disorders? Psychopharmacol Bull 36 (2): 88-104.
50. Mitchell JE, Raymond N, Specker S (1993) A review of the controlled trials of pharmacotherapy in the treatment of bulimia nervosa. Int J Eat Disord 14 (3): 229-47.
51. Walsh BT, Devlin MJ (1995) Pharmacotherapy of bulimia nervosa and binge eating disorder. Addict Behav 20 (6): 757-64.
52. Hartman BK, Faris PL, Kim SW et al (1997) Treatment of bulimia nervosa with ondansetron. Arch Gen Psychiatry 54 (10): 969-70.
53. Faris PL, Kim SW, Meller WH et al (1998) Effect of ondansetron, a 5-HT3 receptor antagonist, on the dynamic association between bulimic behaviors and pain thresholds. Pain 77 (3): 297-303.
54. Faris PL, Kim SW, Meller WH (2000) Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet 355 (9206): 792-7.
55. Hasler WL (2000) 5-HT(3) antagonist therapy of bulimia nervosa: a peripherally active agent for a central nervous system eating disorder? Gastroenterology 119 (1): 271-2.
56. Fung SM, Ferrill MJ (2001) Treatment of bulimia nervosa with ondansetron. Ann Pharmacother 35 (10): 1270-3.
57. Pederson KJ, Roerig JL, Mitchell JE (2003) Towards the pharmacotherapy of eating disorders. Expert Opin Pharmacother 4 (10): 1659-78.